For Immediate Release: November 29, 2017
513-579-9911 x 12523
Medpace Strengthens Medical Leadership in Neuroscience, Rare Disease and Pediatric Drug Development
Michael S. Oldham MD, MPH Joins Medpace as Medical Director
CINCINNATI, OH — (November 29, 2017) – Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO), announced that Michael S. Oldham, MD, MPH has joined Medpace as Medical Director of Medical Affairs. As part of a growing team of physicians at Medpace, Dr. Oldham has a strong background in child and adult neurology, as well as particular interests in drug-resistant pediatric epilepsies and other rare diseases. The company’s unique physician-driven model provides specialized expertise throughout the design and management of a Sponsor’s program, which results in a distinct advantage through greater depth of knowledge and hands-on leadership.
About Michael S. Oldham, MD, MPH
Dr. Michael S. Oldham earned his medical degree from The George Washington University School of Medicine and Health Sciences in Washington DC. His post-graduate medical training includes pediatrics and child neurology at the University of Cincinnati/Cincinnati Children’s Hospital Medical Center and a Clinical Neurophysiology fellowship at the University of California, San Francisco. He holds a Masters of Public Health from the Johns Hopkins University Bloomberg School of Public Health. Prior to joining Medpace, he was the Senior Medical Director for a specialty pharmaceutical company in Louisville, Kentucky, and served as Assistant Professor and Director of Neonatal Neurology in the Division of Child Neurology at the University of Louisville where he focused his clinical efforts on the treatment of children with epilepsy, established the multidisciplinary neonatal neurology program, and was involved in several industry-sponsored clinical trials. He has won numerous awards for his work in neurology and has been published in various peer-reviewed journals.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its physician-led, high-science, and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people across 35 countries.